Amgen showcases a legacy of science, innovation and collaboration in Cambridge

AmgenWhen Amgen (NASDAQ:AMGN) purchased a vacant parcel of land in the heart of Kendall Square in Cambridge, Mass. 25 years ago, the area was far from the thriving biotechnology hub it has since become. In 2001, Amgen, a biotechnology pioneer, completed construction of an eight-story, 297,000-square-foot facility on the site. Now one of the world's leading independent biotechnology companies, Amgen has expanded its presence in Cambridge and today hosted members of the Massachusetts life sciences community and government officials at its newly renovated research and process development facility.

The event commemorated the completion of a renovation featuring next-generation laboratories and offices, a process development scale-up laboratory visible from the exterior and an interactive lobby highlighting Amgen's science and patient stories. Amgen has invested approximately $100 million in the Cambridge facility since 2015, and more than 400 staff are based at the site.

"Amgen's state-of-the-art facility here in Cambridge exemplifies what it means to be at the cutting edge of biomedical research," said Robert A. Bradway, chairman and chief executive officer at Amgen. "Many of the ingredients you need to foster innovation are right here - talented people, the latest technology, and an environment conducive to advancing science. We chose Cambridge as one of our core research hubs because it is an environment with a thriving life sciences ecosystem that encourages innovation."

The site accommodates research scientists with expertise in therapeutic discovery, specifically within medicinal chemistry, molecular engineering and discovery attribute sciences. Process development scientists and engineers support product commercialization and the advancement of manufacturing innovation.

"Massachusetts is a global leader in technology, innovation, research and development because of the early investment and continued impact of companies like Amgen," said Governor Charles Baker. "We welcome Amgen's growth in Cambridge and the future healthcare advancements for patients around the world that will come of their updated state-of-the-art facility."

Amgen's neuroscience research group is based at the site, with efforts focused on migraine, analgesia, Alzheimer's disease, and other chronic neurodegenerative diseases. Scientists within the neuroscience therapeutic area in Cambridge support Amgen's migraine prevention clinical development program by investigating the cellular mechanism of action of the Calcitonin Gene-Related Peptide (CGRP) receptor, furthering the Company's understanding in this area.

"Amgen's ongoing commitment to Cambridge further strengthens Massachusetts' position as a global biosciences beacon," said Senator Edward Markey. "From helping to cure Alzheimer's to preventing migraine, the scientists and staff at Amgen will continue to discover and develop breakthroughs and medicines that will drive the life sciences for generations to come."

The new process development scale-up laboratory provides a dedicated space for staff to test cutting-edge technologies focused on next-generation biomanufacturing. The company embarked on developing an open environment setting, designed for staff to share and communicate ideas easier, to enable more efficient decision-making and to foster greater collaboration amongst staff and the surrounding life sciences community. The lobby showcases interactive, visual elements to describe Amgen's biology-first approach to understanding disease, and patient and research videos highlighting Amgen's focus in cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.

Since 2014, Amgen has entered into collaborations with LabCentral, Boston Children's Hospital, Harvard Department of Molecular and Cellular Biology, as well as others.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

Nucala (mepolizumab) gains FDA approval for two ne…

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjec...

Jeff Settleman, Ph.D., joins Pfizer to lead Oncolo…

Pfizer Inc. (NYSE: PFE) announced that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading al...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Full data from CAROLINA® outcome trial support lon…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardio...

Cleveland researchers test novel gene therapy for …

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Bristol-Myers Squibb announces post-closing leader…

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with ...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Prescription drug costs steadily soar, yet price t…

After reviewing tens of millions of insurance claims for the country’s 49 most popular brand-name prescription drugs, a team from Scripps Research Translational Institute...